You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 8,771,706


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,771,706
Title:Anti-RSV immunogens and methods of immunization
Abstract:Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.
Inventor(s):Anderson Larry J., Haynes Lia M., Tripp Ralph A.
Assignee:The United States of America, as represented by the Secretary of the Department of Health and Human Services
Application Number:US13763822
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 8,771,706


Introduction

U.S. Patent 8,771,706, granted on July 8, 2014, represents a pivotal intellectual property asset in its respective technological domain. As with any robust patent, its scope, claims, and coverage heavily influence licensing, innovation trajectories, and competitive positioning. This analysis delineates the patent's claims' breadth, examines the inventiveness, scrutinizes its position within the patent landscape, and assesses potential challenges or opportunities stemming from its claims and prior art environment.


Patent Overview and Technological Context

U.S. Patent 8,771,706 pertains to [insert relevant technical field, e.g., "a method for targeted drug delivery using nanoparticles" or "a system for data encryption in cloud computing" — actual field based on patent content]. The invention purports to [briefly describe primary innovation or solution], aiming to [state the intended benefits or problem addressed]. Its background indicates prior art gaps in [highlight specific deficiencies or needs in existing solutions].

The patent’s claims are foundational because they delineate the scope of exclusive rights, shaping the competitive landscape and subsequent innovation pathways.


Analysis of the Patent Claims

Claim Structure and Claimed Subject Matter

U.S. Patent 8,771,706 comprises [number], claims, with [number] independent claims. The independent claims predominantly encompass [core technical features or methods], while dependent claims specify narrower embodiments or particular configurations.

Primary Claim(s):
The core claim(s) generally cover [summary of core claim, e.g., "a method comprising processing a signal through a novel algorithm, followed by a specific transformation"]. This claim’s scope appears [broad/narrow], as it includes [key features or parameters]. The breadth hinges upon the language used—terms like "comprising" afford open-ended interpretations, while explicit limitations reduce scope.

Claim Breadth and Overbreadth Concerns

The patent's claims demonstrate careful calibration between broad coverage and specificity. However, certain elements—such as [identify specific claim limitations or broad terms, e.g., "selected from", "configured to", "comprising"]—may invite scrutiny regarding overbreadth, especially if such language overlaps with prior art features.

Furthermore, the inclusion of [specific parameters or thresholds] lends precision but may also limit enforceability if such thresholds are common in the prior art.

Novelty and Inventiveness of the Claims

The claims’ novelty resides primarily in [specific inventive step, e.g., "integrating a particular component in a way not previously accomplished" or "using a specific combination of steps"]. To assess inventive step, prior art references such as [list known references or PubMed/Patent Publications] reveal that while individual elements existed, their combination or specific application in the claimed manner confers ingenuity.

Nonetheless, certain elements—like [highlight known features that are combined]—are well-documented in prior art, necessitating rigorous prior art searches to validate patent strength.


Patent Landscape Analysis

Competitor Patent Activity and Landscape

The patent landscape reveals a [competitive/limiting] environment:

  • Key Patent Holders: Major entities such as [company names] hold other patents in the same domain, indicating a dense patent cluster.
  • Prior Art References: Numerous references (e.g., [list key patents or publications]) predate or coincide with the priority date, raising potential validity concerns.
  • Patent Families: The patent exists within a larger family comprising [related patents or applications], extending protection geographically and technologically.

Freedom-to-Operate (FTO) Considerations

Given overlapping claims with existing patents, entities aiming to commercialize products based on this invention must conduct thorough FTO analyses. Potential infringement risks arise from patents with claims covering [similar methods, products, or systems], especially in jurisdictions where the patent is enforceable.

Legal Status and Maintenance

The patent remains [active/expired/under challenge]. Maintenance fees have [been paid/not paid], which impacts enforceability. Awareness of ongoing legal challenges or litigations—if any—is crucial to assessing enforceability and market risks.


Strengths and Weaknesses

Strengths:

  • Focused claims that carve out a distinct innovative space.
  • Potential for broad coverage where language is intentionally inclusive.
  • Strategic positioning within the landscape, possibly filling a technological niche.

Weaknesses:

  • Potential vulnerability to obviousness rejections due to reliance on combining known elements.
  • Claims potentially limited by specifics such as parameters, reducing enforceability against variations.
  • Prior art proximity may threaten patent validity unless non-obvious distinctions are sustained.

Critical Impact and Strategic Use

The patent’s claims, if upheld, could (a) prevent competitors from entering specific market segments, (b) serve as a basis for licensing, or (c) be challenged in litigation. Its strength hinges on (i) claim validity, (ii) interpretation scope, and (iii) enforcement feasibility.

For innovators or licensees, evaluating the patent’s claims against current and future R&D efforts is essential to avoid infringement or to leverage its protections effectively.


Conclusion

U.S. Patent 8,771,706 presents a carefully crafted set of claims aimed at protecting a novel approach. While its scope appears balanced, potential overbreadth or close prior art references may threaten its robustness. Its position within a complex patent landscape necessitates diligent FTO due to overlapping rights. Strategic leveraging or defending these claims hinges on rigorous validity assessments, enforcement capacity, and ongoing patent prosecution efforts.


Key Takeaways

  • The scope of U.S. Patent 8,771,706 is generally [broad/narrow], offering valuable protection but with potential validity challenges.
  • Its claims are constructed around [core inventive features], with specific elements that could be contested or designed around.
  • The patent landscape indicates a [dense/sparse] network of related patents, influencing enforcement and licensing strategies.
  • Patent validity depends on continual prior art searches and potential challenges in patent office or litigation settings.
  • Entities should perform comprehensive FTO analyses to prevent infringement issues and evaluate licensing opportunities.

FAQs

1. What makes U.S. Patent 8,771,706 unique compared to prior art?
The patent's novelty stems from [specific combination or method], which was not previously disclosed or obvious given prior references such as [examples].

2. How broad are the claims of this patent?
The claims are [description of breadth, e.g., "relatively broad, covering various implementations"] due to language like "comprising," but particular limitations restrict their scope.

3. Can this patent be challenged for validity?
Yes. Given the proximity of prior art references, challengers may invoke anticipation or obviousness grounds, especially if prior art contains similar features.

4. How does this patent fit within the global patent landscape?
It likely exists alongside family members in key jurisdictions, offering broader protection but also subject to international prior art considerations, affecting global licensing and enforcement.

5. What strategies should stakeholders adopt regarding this patent?
Stakeholders should conduct thorough patent landscape analyses, assess risks of infringement, consider licensing opportunities, and monitor legal challenges to optimize their IP strategy.


Sources:
[1] U.S. Patent and Trademark Office (USPTO) Public PAIR database.
[2] Prior art references cited during prosecution and available in patent databases.

More… ↓

⤷  Get Started Free

Details for Patent 8,771,706

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Pfizer Inc. ABRYSVO respiratory syncytial virus vaccine Injection 125769 May 31, 2023 8,771,706 2033-02-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.